Related Experiment Video
Updated: Jan 25, 2026

In Vivo Biosensor Tracks Non-apoptotic Caspase Activity in Drosophila
Published on: November 27, 2016
Caspase-3 probes for PET imaging of apoptotic tumor response to anticancer therapy
Filipe Elvas1, Tom Vanden Berghe, Yves Adriaenssens
1Molecular Imaging Center Antwerp, University of Antwerp, 2610 Wilrijk, Belgium. filipe.elvas@uantwerpen.be.
Abstract:
Apoptosis is a highly regulated process involved in the normal organism development and homeostasis. In the context of anticancer therapy, apoptosis is also studied intensively in an attempt to induce cell death in cancer cells. Caspase activation is a known key event in the apoptotic process. In particular, active caspase-3 and -7 are the common effectors in several apoptotic pathways, therefore effector caspase activation may be a promising biomarker for response evaluation to anticancer therapy. Quantitative imaging of apoptosis in vivo could provide early assessment of therapeutic effectiveness and could also be used in drug development to evaluate the efficacy as well as potential toxicity of novel treatments. Positron Emission Tomography (PET) is a highly sensitive molecular imaging modality that allows non-invasive in vivo imaging of biological processes such as apoptosis by using radiolabeled probes. Here we describe the development and evaluation of fluorine-18-labeled caspase-3 activity-based probes (ABPs) for PET imaging of apoptosis. ABPs were selected by screening of a small library of fluorine-19-labeled DEVD peptides containing different electrophilic warhead groups. An acyloxymethyl ketone was identified with low nanomolar affinity for caspase-3 and was radiolabeled with fluorine-18. The resulting radiotracer, [18F]MICA-302, showed good labeling of active caspase-3 in vitro and favorable pharmacokinetic properties. A μPET imaging experiment in colorectal tumor xenografts demonstrated an increased tumor accumulation of [18F]MICA-302 in drug-treated versus control animals. Therefore, our data suggest this radiotracer may be useful for clinical PET imaging of response to anticancer therapy.
Insights
Researchers developed a new PET imaging probe, [18F]MICA-302, to detect apoptosis by targeting active caspase-3. This tool could help assess anticancer therapy effectiveness non-invasively in patients.
Area of Science:
- Molecular Imaging
- Oncology
- Biochemistry
Background:
- Apoptosis is crucial for development and homeostasis, and its induction is a key goal in cancer therapy.
- Caspase activation, particularly caspase-3 and -7, is a central event in apoptosis and a potential biomarker for treatment response.
- Non-invasive in vivo imaging of apoptosis can enable early assessment of therapeutic efficacy and drug development.
Purpose of the Study:
- To develop and evaluate novel fluorine-18-labeled caspase-3 activity-based probes (ABPs) for Positron Emission Tomography (PET) imaging of apoptosis.
- To identify a suitable ABP with high affinity for caspase-3 and favorable properties for in vivo imaging.
- To assess the potential of the developed radiotracer for monitoring response to anticancer therapy.
Main Methods:
- Screening of fluorine-19-labeled DEVD peptides with different electrophilic warheads to identify high-affinity ABPs.
- Radiolabeling of the lead compound with fluorine-18 to create the PET tracer [18F]MICA-302.
- In vitro evaluation of [18F]MICA-302 for caspase-3 labeling and pharmacokinetic profiling.
- In vivo microPET imaging in colorectal tumor xenografts to assess tumor accumulation in response to drug treatment.
Main Results:
- An acyloxymethyl ketone-containing DEVD peptide was identified with low nanomolar affinity for caspase-3.
- [18F]MICA-302 demonstrated effective labeling of active caspase-3 in vitro and favorable pharmacokinetic properties.
- μPET imaging revealed increased tumor accumulation of [18F]MICA-302 in drug-treated tumor xenografts compared to controls.
Conclusions:
- The developed fluorine-18-labeled ABP, [18F]MICA-302, shows promise for PET imaging of apoptosis.
- This radiotracer may serve as a valuable tool for non-invasive, in vivo assessment of response to anticancer therapies.
- Further clinical evaluation is warranted to establish its utility in patient management and drug development.
More Related Videos
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010
Related Concept Videos
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
Gene Therapy
Group Therapy